Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|PACCT-1||ECOG||Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1501||SWOG||Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer; Phase III||Cancer Prevention and Control CIRB||Available to Open|
|EAZ171||ECOG-ACRIN||Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women||Cancer Prevention and Control CIRB||Available to Open|
|ACCRN07||COG||Protocol for the Enrollment on the Official COG Registry; The Childhood Cancer Research Network (CCRN)||Pediatric CIRB||Available to Open|
|CALGB-70301||CALGB||Quality of Life; Employment; and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes: Companion to CALGB 40101||Adult CIRB - Late Phase Emphasis||Completed|
|ACNS0232||COG||Radiotherapy Alone vs. Chemotherapy Followed by Response-based Radiotherapy for Newly Diagnosed Primary CNS Germinoma: A Phase III Group-Wide Study||Pediatric CIRB||Completed|
|A081105||Alliance||Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1703||SWOG||Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer||Cancer Prevention and Control CIRB||Available to Open|
|10146||ETCTN||Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) in patients with metastatic triple negative breast cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|10013||ETCTN||Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (TNBC)||Adult CIRB - Early Phase Emphasis||Available to Open|